An Open Label Phase II Study of Aprepitant for Multi-Day Moderately-High to Highly Emetogenic Chemotherapy Regimens
Latest Information Update: 10 May 2022
At a glance
- Drugs Aprepitant (Primary) ; Dexamethasone; Ondansetron; Prochlorperazine
- Indications Chemotherapy-induced nausea and vomiting
- Focus Therapeutic Use
- 05 Aug 2009 Actual patient number (22) and actual end date (1 Jan 2009) added as reported by ClinicalTrials.gov.
- 05 Aug 2009 Actual patient number (22) and actual end date (1 Jan 2009) added as reported by ClinicalTrials.gov.
- 05 Aug 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.